Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.

Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB
Vaccine. 2008 26 (49): 6225-31

PMID: 18692108 · PMCID: PMC4477808 · DOI:10.1016/j.vaccine.2008.07.052

Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals. It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making the virus the leading cause of liver transplantation in the world. Currently there is no vaccine for HCV. In this study, we have taken a multi-step approach to develop a novel genotype 1a/1b consensus HCV NS3/NS4A DNA vaccine able to induce strong cellular immunity. We show that this construct is able to induce strong anti-NS3/NS4A T cell responses in C57BL/6 mice, as well as, in Rhesus macaques. Our data suggest that DNA vaccines encoding HCV proteins NS3/NS4A merit further study in the context of future prophylactic and therapeutic HCV T cell based vaccines.

MeSH Terms (21)

Amino Acid Sequence Animals Carrier Proteins Cell Separation Electroporation Enzyme-Linked Immunosorbent Assay Epitope Mapping Fluorescent Antibody Technique Genotype Hepacivirus Immunity, Cellular Immunization Interferon-gamma Macaca mulatta Mice Mice, Inbred C57BL Molecular Sequence Data Spleen Vaccines, DNA Viral Nonstructural Proteins Viral Proteins

Connections (1)

This publication is referenced by other Labnodes entities: